clinical trial · NCT04302025
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.·phase2·recruiting·n = 99
Non-small Cell Lung CancerAlectinibEntrectinibVemurafenibCobimetinibPralsetinibAtezolizumabSBRTResection
brief summary
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
started
Nov 6, 2020
primary completion
Nov 30, 2026
completion
May 30, 2030
last updated
Jun 9, 2026
official title
NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol